PubMed Health⌕ Search

Biomedical subjects

P Pronzato

Publications and source records attributed to P Pronzato.

At least 91 records · Page 5Linked to original sources
PubMed1985

Aminoglutethimide as second-line endocrine treatment in metastatic breast cancer.

Aminoglutethimide, a drug known to block adrenal steroidogenesis and peripheral aromatization of androgens to estrogens, has been found effective in the treatment of breast cancer. The drug has been used in our Institute to treat 71 consecutive metastatic breast cancer patients. Of 67 patients evaluable for response, 9 (13.4%) have achieved a partial response, 30 (44.7%) stable disease, and 28 (41.7%) progression of disease. Four patients were taken off the therapy because of drug-related toxicity.

Age Factors↗
PubMed1984

Mitomycin C and 5-fluorouracil as second choice treatment in advanced breast cancer patients.

Twenty-six patients with advanced breast cancer, (12 previously treated with adriamycin-containing regimens, 14 not exposed to adriamycin because of poor cardiac performance), were treated with combination chemotherapy including mitomycin C plus 5-fluorouracil. Objective response was seen in 7/66 patients (26.9%) with a statistically higher response rate in patients with fewer than 2 metastatic sites. Because of mild toxicity this regimen can be safely used as second-line chemotherapy for heavily pretreated patients and as first-line treatment in patients with poor cardiac performance.

Adult↗
PubMed1982

[Influence of alcohol intake and smoking on plasma HDL cholesterol in active and sedentary subjects].

The effect of physical activity, of smoking habit and alcohol assumption on plasma HDL-cholesterol has been evaluated in 40 normolipidaemic male active subjects and in 43 non-active ones. The comparison have been performed after covariance adjustment for potentially confounding variables. Physical activity increases and smoking habit decreases HDL-cholesterol plasma levels; no effects depending on alcohol consumption have been found.

Adult↗
PubMed1979

[Preliminary considerations on the behavior of single plasmatic free fatty acids in obese subjects exposed to lipolytic stimulus before and after a period of caloric restriction].

The compositions of the plasma free fatty acid picture changes in relation of the metabolic situation, which is not that theoretically predictable from the adipocyte triglycerides. After a meal, this is due to the existence of a labile storage pool, which derives its features directly from those of the food lipids. In the fasting subject, when this compartment has exhausted its remains, the failure of the NEFA picture to correspond to that of the fats constituting the stabel pool may be attributable to selective release, or to preferential utilisation of each fatty acid. Analysis of the composition performed a very short time after a supramaximal lipolytic stimulus, i.e. when the release of fatty acids surpasses their peripheral removal, by confirming the differences noted under basal conditions, suggests that the first theory used to explain the phenomenon is most likely the correct one.

Adult↗
PubMedDate not supplied

Analysis of time to response to chemotherapy in 316 metastatic breast cancer patients.

Chemotherapy is a major tool for metastatic breast cancer treatment. In this study, a series of 316 patients have been analyzed to evaluate the time needed to reach tumor response by means of combination chemotherapy. Twenty-five percent of patients responded within 3 months and virtually all responses occurred within 7.5 months. The time curves of response (any) and best response are superimposable. A subset analysis has shown that the following pretreatment characteristics predict a significantly longer time to response: prior exposure to adjuvant chemotherapy, nodal positivity at diagnosis, no previous endocrine treatment and osseous metastases.

Age Factors↗
PubMedDate not supplied

Carboplatin and etoposide as outpatient treatment of advanced non-small-cell lung cancer.

Twenty-four outpatients with locally advanced (inoperable or unsuitable for radical radiotherapy) or metastatic non-small-cell lung cancer were treated with carboplatin (300 mg/m2 day 1)+etoposide (120 mg/2 day 1-3), every 3 weeks. Two patients died of disease progression before completing at least 2 cycles of chemotherapy. Four patients (16.7%) obtained a partial response, 10 had disease stabilization (41.7%) and 8 progressed (33.3%). Median overall survival was 8 months (range 1-22). Toxicity was moderate, with no nephro-, neuro- or ototoxicity.

Aged↗
PubMedDate not supplied

A randomized trial of chemotherapy with or without estrogenic recruitment in locally advanced breast cancer. North-West Oncology Group (GONO) Study, Italy.

The present phase III trial was carried out to verify whether a kinetic recruitment induced by low doses of diethylstilbestrol (DES) could increase the killing efficacy of chemotherapy in patients with locally advanced breast cancer. One-hundred and seventeen untreated patients with locally advanced breast cancer (stage IIIA/IIIB) were randomized to receive 3 courses of primary chemotherapy consisting of cyclophosphamide (600 mg/m2 i.v.), doxorubicin (50 mg/m2 i.v.) and fluorouracil (600 mg/m2 i.v.) (CAF) on day 1, or DES-CAF (DES, 1 mg orally days 1-3, CAF on day 4). The courses were repeated every 3 weeks. The patients who achieved an objective response were submitted to mastectomy followed by 3 courses of CAF alternated with 3 courses of CMF (cyclophosphamide, 600 mg/m2 i.v.; methotrexate, 40 mg/m2 i.v.; fluorouracil, 600 mg/m2 i.v.), with or without DES. The two treatment arms were well balanced in terms of clinical and pathologic features. There was no significant difference in response rates to induction chemotherapy between the two treatment arms (objective response rate, 63.3% for CAF and 56.1% for DES-CAF). Median overall survival was 49 and 47 months and median progression-free survival was 24 and 21 months for CAF and DES-CAF patients, respectively. Toxicity was not significantly different in the two groups, with the exception of leukopenia: DES chemotherapy was significantly more myelotoxic than the standard treatment, which resulted in a significant reduction in the actual dose intensity. In spite of the attractive experimental evidence, we conclude that so far there is no clinical advantage in the combination of estrogen and chemotherapy. Further research is needed to investigate different schedules of chemotherapy and hormones, or to test the possibility of combining various mitogens.

Antineoplastic Agents, Hormonal↗